Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Genomics and Genome Evolution of Mycobacterium Tuberculosis

A glimpse into the past and predictions for the future: the molecular evolution of the tuberculosis agent

Understanding the epidemiology and pathogenesis of Mycobacterium tuberculosis with non-redundant pangenome and population genetics

Evolution and emergence of Mycobacterium tuberculosis

Progress on the DNA Diagnosis and Genomics of Mycobacterium Tuberculosis

Progress in the application of whole genome sequencing in tuberculosis research

Research Progress on Genetic Control of Host Susceptibility to Tuberculosis.

Comparative analysis of mycobacterium and related actinomycetes yields insight into the evolution of mycobacterium tuberculosis pathogenesis

Mycobacterium Tuberculosis Biology Revealed by Proteome Profiling and Integration of Multi-Omics Data-Proteomics Insight into M-Tuberculosis Systems Biology

Genomics of nontuberculous mycobacteria

The past, present and future of tuberculosis treatment.

Current applications of next-generation sequencing technology in Mycobacterium tuberculosis research

An overview of next generation sequencing strategies and genomics tools used for tuberculosis research

Genetic diversity, evolution and drug resistance of Mycobacterium tuberculosis lineage 2

Comprehensive pan-genome analysis of Mycobacterium marinum: insights into genomic diversity, evolution, and pathogenicity

Mycobacterium tuberculosis genetic diversity and differential virulence

Tuberculosis: Current state of knowledge: An Epilogue

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

Large-scale Pan Genomic Analysis of Mycobacterium tuberculosis Reveals Key Insights Into Molecular Evolutionary Rate of Specific Processes and Functions

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.